“As firms attempt to adapt to ever-changing political and technological circumstances, global M&A has stuttered over the summer, following a strong showing in the first half of the year,” reports Mergermarket in its “Global & Regional M&A Report Q3 2017”.
Despite this market trend, Goodwin’s international technology, life sciences, and private equity teams have been exceptionally busy across all geographies and sectors. The firm surged in Mergermarket’s league tables, moving up (over the same time period last year) across a number of deal count categories, including:
- #2 Global and US exits (up 3 spots)
- #3 Global buyouts + exits (up 5 spots)
- #3 US buyouts + exits (up 17 spots)
- #4 France M&A deals (up 54 spots)
- #5 US M&A deals (up 5 spots)
- #6 Global M&A deals (up 18 spots)
- #7 Europe buyouts + exits (up 47 spots)
Click here to view the full report (via Mergermarket).
With more than 180 lawyers, Goodwin’s Technology Companies practice is consistently rated in the top five most active of all law firms for venture capital, IPOs and M&A. The practice supports clients at all stages of the corporate life cycle with legal advisory related to company formation, IP protection, licensing, commercial agreements and venture financing to IPOs, M&A, corporate governance, board matters and more. The practice also represents a number of leading venture capital firms on fund formation, investments and other matters.
Goodwin’s Life Sciences Practice was recently named “Practice Group of the Year” by Law360, which called the firm “a top choice for high-profile pharmaceutical clients, particularly in licensing deals, mergers and acquisitions, and initial public offerings.” Goodwin has been consistently recognized by U.S. News and World Report - Best Lawyers as “Biotech Firm of Year,” including in 2017.
The firm’s internationally recognized Private Equity Practice focuses on buyouts, recapitalizations, growth equity investments, and portfolio company transactions in the United States and internationally with a leading position in the U.S. middle markets and growth equity. With a team of over 200 lawyers, the practice covers the full life cycle of clients’ investments – from fund formation to exit and everything in between.